Gross Profit Comparison: BioCryst Pharmaceuticals, Inc. and Evotec SE Trends

BioCryst vs. Evotec: A Decade of Profit Trends

__timestamp	BioCryst Pharmaceuticals, Inc.	Evotec SE
Wednesday, January 1, 2014	13486000	29378000
Thursday, January 1, 2015	46361000	37987000
Friday, January 1, 2016	23654000	58554000
Sunday, January 1, 2017	23484000	82568000
Monday, January 1, 2018	20182000	112016000
Tuesday, January 1, 2019	44734000	132891000
Wednesday, January 1, 2020	16136000	125743000
Friday, January 1, 2021	149906000	151543000
Saturday, January 1, 2022	264233000	174065000
Sunday, January 1, 2023	326751000	175051000

Unleashing insights

A Tale of Two Biotech Giants: BioCryst vs. Evotec

In the ever-evolving world of biotechnology, financial performance is a key indicator of a company's potential. Over the past decade, BioCryst Pharmaceuticals, Inc. and Evotec SE have showcased intriguing trends in their gross profits. Starting in 2014, Evotec led the race with a gross profit nearly double that of BioCryst. However, by 2023, BioCryst surged ahead, achieving a remarkable 142% increase in gross profit compared to its 2014 figures, while Evotec's growth was a steady 60% over the same period.

This financial journey highlights BioCryst's strategic advancements and market adaptability, especially evident in 2021 when it nearly matched Evotec's gross profit. As the biotech sector continues to innovate, these trends offer valuable insights into the competitive dynamics and growth trajectories of these industry leaders.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025